Shanxi Kangbao Biological Product Co., Ltd.;Institute of Pathogen Biology, Chinese Academy of Medical Sciences
发明人:
He, Yuxian,Chong, Huihui,Zhu, Yuanmei
申请号：
AU2017410525
公开号：
AU2017410525A1
申请日:
2017.04.18
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
A potent HIV inhibiting lipopeptide, a derivative thereof, a pharmaceutical composition thereof and use thereof. The lipopeptide is as follows: a) the lipopeptide is formed by connecting a polypeptide having antiviral activity to a lipophilic compound which is linked to a carboxy-terminal of the polypeptide, or b) the lipopeptide is formed by connecting a polypeptide having antiviral activity to a terminal protecting group and a lipophilic compound which is linked to a carboxy-terminal of the polypeptide, wherein the terminal protecting group is an amino terminal protecting group and/or a carboxy-terminal protecting group； the polypeptide sequence consists of 28 amino acid residues, corresponding to the 127th-154th amino acids in the HIV-1 strain HXB2 gp41 sequence. Compared with T-20, the anti-HIV activity of the lipopeptide is several thousands times or even tens of thousands times higher, and is also significantly higher than that of anti-HIV lipopeptides C34-Chol, LP-19, and the like.
